ENABLE-2
About us
An interdisciplinary team of international experts guiding researchers with early-stage antibacterial programmes.
![](/images/200.58b4b52318eeff6cc4c4a3/1713425714131/What%20ENABLE-2%20can%20do%20for%20you%20711%20400.jpg)
Current programmes
ENABLE-2 is currently supporting five promising programmes in the pursuit of new antibiotics.
![](/images/200.58b4b52318eeff6cc4c66b/1713426370689/Current%20programmes%20711%20400.jpg)
News
Read the latest updates on programmes and progress from the antibacterial drug discovery platform ENABLE-2
![](/images/200.58b4b52318eeff6cc4c36222/1713443139022/news%20big%20glasses.jpg)
ENABLE-2 Platform
The team progressing the ENABLE-2 programmes
Contact us
Contact the ENABLE-2 management team
Apply to ENABLE-2
We accept applications from researchers at European publicly-funded universities and research institutes.
![](/images/200.58b4b52318eeff6cc4c68c/1713426452505/Apply%20to%20ENABLE2%20711%20400.jpg)
ENABLE-2 Incubator
ENABLE-2 Incubator Hit identification and validation evaluates the antibiotic potential of novel compounds
![](/images/200.46d706421905a1e8b637d6e/1719584186260/Identification.jpg)
Hit to Lead programme
ENABLE-2 is set up with a strong focus on developing small molecule programmes in the Hit to Lead stage.
![](/images/200.46d706421905a1e8b637b6b/1719583489484/Hit%20to%20lead.jpg)
Welcome to ENABLE-2
ENABLE-2 is an antibacterial drug discovery platform with focus on the early stages of antibiotic discovery and development. ENABLE-2 supports the development of direct acting systemic antibacterial compounds to ensure a sustainable flow of new antibacterial drug candidates into the development pipeline.
ENABLE-2 is based on learnings from ENABLE (Innovative Medicines Initiative) and supported by the Swedish Research Council and the National Research Programme on Antibiotic Resistance.
![ENABLE2 logotyper](/images/200.58b4b52318eeff6cc4c303/1713424731384/Logotyper%20ENABLE2.jpg)